New Developments in Insulin Therapy
The main purpose of rapid insulins is to regulate postprandial glucose excursions. Three insulin analogs (aspart, lispro, and glulisine) were created through changes to the amino acid sequence in the 1990s and the early 2000s. Basal insulin formulation improvements target longer and flatter time-action profiles. By creating insulin hexamers that remain stable after injection, this can be accomplished. Such insulins offer more convenience (e.g., fewer injections), flexibility (e.g., the timing of doses), and a lower risk of hypoglycemia.